Cardiovascular disease Archives

News and Trends 15 Apr 2015

Heart Metabolics bargain with the FDA for a single Phase III

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM). The company, focused on the development of drugs […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Apr 2015

Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial […]

April 11, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 7 Apr 2015

A New Key Strategic Collaboration Between BMS and UniQure

Last month, Bristol-Myers Squibb (BMS) and UniQure, the Dutch pioneer in human gene therapy, were at the forefront of the scene after having agreed on two collaborations, respectively, an agreement between Bavarian Nordic & BMS and a collaboration between Sympromics & UniQure. A few days ago, they announced an exclusive strategic collaboration to develop gene therapies for cardiovascular […]

April 7, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 Apr 2015

Interview with CELLPROTHERA, the regenerative medicine pioneer

CellProthera is a medical biotech company founded in 2008 in Mulhouse, France. The young innovative company focuses on the use of blood peripheral stem cells. CellProthera is the origin of a revolutionary therapy allowing the regeneration of myocardial tissue following acute myocardial infarct (AMI) by injection of a cell graft containing autologous adult stem cells […]

April 2, 2015 - 7 minutesmins - By Nicolas Sainte-Foie

News and Trends 12 Feb 2015

Neurostimulation, an Innovative Approach to Treat Heart Failure

The revolutionary Equilia system, meant to treat heart failure, has been successfully implanted for the first time in a clinical study . The developer of the system, Sorin Group, is an Italian medical device company, leader in the treatment of cardiovascular diseases. Heart failure is a chronic progressive disease in which the heart can no longer […]

February 12, 2015 - 2 minutesmins - By Lourdes Riquelme

LoneStar Heart Hydrogel advanced heart attacks

News and Trends 4 Oct 2014

A Hydrogel to treat Advanced Heart Failure in Europe

LoneStar Heart, Inc. announced that it received the CE Mark (European Conformity) for its Algisyl-LVR® hydrogel implant,a product for the treatment of advanced heart failure (HF). The CE Mark indicates a product’s compliance with European Union legislation and that it can be sold throughout the European Economic Area. Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is […]

October 4, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, […]

September 3, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 31 Aug 2014

Why should you drink tea instead of coffee?

Drinking tea reduces non-cardiovascular mortality by 24%, reveals a study in 131 000 people presented at ESC Congress today by Professor Nicolas Danchin from France. Professor Danchin said: “If you have to choose between tea or coffee it’s probably better to drink tea. Coffee and tea are important components of our way of life. Their […]

August 31, 2014 - 4 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us